Abstract
Reactive oxygen species (ROS) are a group of highly reactive chemicals under tight control of intracellular antioxidants. The balance in oxidation-antioxidation is essential for maintaining normal cell functions, and any imbalance could lead to a wide range of diseases including cancer. The intracellular level of ROS is generally elevated in cancer cells, revealing a critical role of ROS in the process of carcinogenesis and cancer progression. Conversely, there is also evidence showing that ROS can act as cancer suppressors. This may be due to the varying antioxidant capacities of different cancers. These findings indicate a complex redox state in cancer cells. In this review we summarize the main features of ROS and their functions with respect to cancer initiation, hallmarks of cancer, and signaling in cancer cells. ROSelevating and ROS-depleting anticancer strategies and their mechanisms are thoroughly discussed. We argue that the rationale for therapy choice depends on a complete understanding of cancer cell redox state, namely, the “redox signaling signature” of cancer.
Keywords: Antioxidants, cancer biology, cancer progression, cancer therapy, carcinogenesis, reactive oxygen species.
Current Medicinal Chemistry
Title:Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Volume: 20 Issue: 30
Author(s): Y. Yang, S. Karakhanova, J. Werner and A. V. Bazhin
Affiliation:
Keywords: Antioxidants, cancer biology, cancer progression, cancer therapy, carcinogenesis, reactive oxygen species.
Abstract: Reactive oxygen species (ROS) are a group of highly reactive chemicals under tight control of intracellular antioxidants. The balance in oxidation-antioxidation is essential for maintaining normal cell functions, and any imbalance could lead to a wide range of diseases including cancer. The intracellular level of ROS is generally elevated in cancer cells, revealing a critical role of ROS in the process of carcinogenesis and cancer progression. Conversely, there is also evidence showing that ROS can act as cancer suppressors. This may be due to the varying antioxidant capacities of different cancers. These findings indicate a complex redox state in cancer cells. In this review we summarize the main features of ROS and their functions with respect to cancer initiation, hallmarks of cancer, and signaling in cancer cells. ROSelevating and ROS-depleting anticancer strategies and their mechanisms are thoroughly discussed. We argue that the rationale for therapy choice depends on a complete understanding of cancer cell redox state, namely, the “redox signaling signature” of cancer.
Export Options
About this article
Cite this article as:
Yang Y., Karakhanova S., Werner J. and Bazhin V. A., Reactive Oxygen Species in Cancer Biology and Anticancer Therapy, Current Medicinal Chemistry 2013; 20 (30) . https://dx.doi.org/10.2174/0929867311320999165
DOI https://dx.doi.org/10.2174/0929867311320999165 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Uropathogenic Escherichia coli Mediated Urinary Tract Infection
Current Drug Targets Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology 99mTc-labeling of Peptidomimetic Antagonist to Selectively Target αvβ3 Receptor-Positive Tumor: Comparison of PDA and EDDA as Co-Ligands
Current Radiopharmaceuticals The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis - Current Status
Current Medicinal Chemistry Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
Current Radiopharmaceuticals Autoimmune Neuromuscular Disorders
Current Neuropharmacology Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Preclinical Toxicity of Paclitaxel Biopolymer Formulation
Anti-Cancer Agents in Medicinal Chemistry Choline Kinase Active Site Provides Features for Designing Versatile Inhibitors
Current Topics in Medicinal Chemistry Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Immunosensors in Early Cancer Diagnostics: From Individual to Multiple Biomarker Assays
Current Medicinal Chemistry Recent Advances in Delivery of Cytokines, Growth Factors, and Molecules of Therapeutic Interest from Hyaluronan-based Hydrogels
Current Tissue Engineering (Discontinued) Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine